MiMedx touts data from study of AmnioFix, EpiFix allograft

MiMedx (NSDQ:MDXG) today announced the publication of a study of its AmnioFix and EpiFix allografts in treating myocardial infarction patients, touting enhanced vascularization and recruitment of autologous stem cells within infarcted cardiac tissue. Data from the study was published in the Journal of Cardiology & Cardiovascular Therapy, the Marietta, Ga.-based company said. “There is a critical need for novel and innovative therapies for effective treatments following myocardial infarction and to promote regeneration of cardiac tissues. At present, total heart transplants and left ventricular assist devices are the primary forms of treatment and these treatments have significant limitations and substantial costs.  The ability of dHACM to attenuate damage or promote cardiac repair is worthy of very serious consideration in the cardiac care community. This scientific study is the first of its kind and the first published report confirming that dHACM may have positive effects in protecting cardiac tissue or promoting repair following acute myocardial infarction or heart attack,” Chair & CEO Parker Petit said in prepared remarks. The study aimed to examine the use of MiMedx’s AmnioFix and EpiFix dehydrated human amnion/chorion membrane allografts in treating patients who have had acute myocardial infarctions, and explore the patches ability to prevent cardiac damage and promote healing. Treatment of infarcted cardiac tissue with the patches resulted i...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Regenerative Medicine MiMedx Group Inc. Source Type: news